GlaxoSmithKline PLC ADR (GSK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has a cash flow conversion efficiency ratio of 0.050x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.14 Billion) by net assets ($22.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of GlaxoSmithKline PLC ADR to measure how many days the company can operate on defensive assets alone.
GlaxoSmithKline PLC ADR - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlaxoSmithKline PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Merchants Bank Co Ltd
SHG:600036
|
0.030x |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
N/A |
|
Altria Group
NYSE:MO
|
-0.948x |
|
PDD Holdings Inc.
NASDAQ:PDD
|
0.110x |
|
Starbucks Corporation
NASDAQ:SBUX
|
-0.043x |
|
HDFC Bank Limited
F:HDFA
|
N/A |
|
Parker-Hannifin Corporation
NYSE:PH
|
0.067x |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
0.073x |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC ADR (1990–2025)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC ADR from 1990 to 2025. For the full company profile with market capitalisation and key ratios, see market value of GlaxoSmithKline PLC ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.99 Billion | $7.14 Billion | 0.447x | -10.83% |
| 2024-12-31 | $13.09 Billion | $6.55 Billion | 0.501x | +3.53% |
| 2023-12-31 | $16.31 Billion | $7.89 Billion | 0.484x | -34.02% |
| 2022-12-31 | $10.10 Billion | $7.40 Billion | 0.733x | +166.55% |
| 2021-12-31 | $28.91 Billion | $7.95 Billion | 0.275x | -7.30% |
| 2020-12-31 | $28.44 Billion | $8.44 Billion | 0.297x | -10.01% |
| 2019-12-31 | $24.32 Billion | $8.02 Billion | 0.330x | -85.62% |
| 2018-12-31 | $3.67 Billion | $8.42 Billion | 2.293x | +15.66% |
| 2017-12-31 | $3.49 Billion | $6.92 Billion | 1.983x | +51.46% |
| 2016-12-31 | $4.96 Billion | $6.50 Billion | 1.309x | +352.40% |
| 2015-12-31 | $8.88 Billion | $2.57 Billion | 0.289x | -72.41% |
| 2014-12-31 | $4.94 Billion | $5.18 Billion | 1.049x | +13.43% |
| 2013-12-31 | $7.81 Billion | $7.22 Billion | 0.924x | +42.57% |
| 2012-12-31 | $6.75 Billion | $4.38 Billion | 0.648x | -8.42% |
| 2011-12-31 | $8.83 Billion | $6.25 Billion | 0.708x | +1.52% |
| 2010-12-31 | $9.74 Billion | $6.80 Billion | 0.697x | -4.45% |
| 2009-12-31 | $10.74 Billion | $7.84 Billion | 0.730x | -16.95% |
| 2008-12-31 | $8.32 Billion | $7.31 Billion | 0.879x | +50.31% |
| 2007-12-31 | $9.91 Billion | $5.79 Billion | 0.585x | +42.54% |
| 2006-12-31 | $9.65 Billion | $3.96 Billion | 0.410x | -44.42% |
| 2005-12-31 | $7.57 Billion | $5.59 Billion | 0.738x | -8.08% |
| 2004-12-31 | $5.94 Billion | $4.77 Billion | 0.803x | +39.91% |
| 2003-12-31 | $8.45 Billion | $4.85 Billion | 0.574x | +38.56% |
| 2002-12-31 | $7.39 Billion | $3.06 Billion | 0.414x | -24.54% |
| 2001-12-31 | $8.40 Billion | $4.61 Billion | 0.549x | +165.41% |
| 2000-12-31 | $8.96 Billion | $1.85 Billion | 0.207x | +29.48% |
| 1999-12-31 | $3.19 Billion | $510.00 Million | 0.160x | +7.83% |
| 1998-12-31 | $2.77 Billion | $410.00 Million | 0.148x | -54.48% |
| 1997-12-31 | $1.89 Billion | $615.00 Million | 0.325x | -51.44% |
| 1996-12-31 | $1.27 Billion | $849.00 Million | 0.670x | -88.17% |
| 1995-12-31 | $221.00 Million | $1.25 Billion | 5.665x | +32.94% |
| 1994-12-31 | $574.69 Million | $2.45 Billion | 4.261x | +1983.79% |
| 1993-12-31 | $5.15 Billion | $1.05 Billion | 0.205x | +2.74% |
| 1992-12-31 | $4.66 Billion | $927.00 Million | 0.199x | +10.25% |
| 1991-12-31 | $3.64 Billion | $657.00 Million | 0.181x | -3.65% |
| 1990-12-31 | $3.28 Billion | $615.00 Million | 0.187x | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more